Par, Glenmark strike deal on generic Zetia; Actavis aims for China growth with Beijing office;

 @FiercePharma: GSK exec pressured EHJ to quash Nissen article. Story | Follow @FiercePharma

BIO 2010: E&Y: 2009 forever changed the biopharma industry. News

BIO 2010: What makes partnerships work? Story

BIO 2010: Alliance: Pfizer, J&J lead regenerative medicine charge. Story

> Par Pharmaceutical inked an exclusive licensing agreement with fellow generics maker Glenmark to market the generic version of Merck's cholesterol drug Zetia; Glenmark believes it has first-to-file status, which would offer 180 days of exclusivity once the copycat is approved. Par release

> Actavis has established a regional office for China in Beijing, with staff aimed at registering its products for sale in the country and at marketing and sales of those meds. Actavis release

> An Albuquerque woman has sued Merck over Gardasil, a vaccine intended to protect women from cervical cancer, alleging it caused physical and behavioral problems in her teenage daughter. Report

> Valeant Pharmaceuticals' first-quarter earnings rose 15 percent as the company announced plans to acquire a special pharmaceutical company focused on opthamology for about $318 million. Report (sub. req.)

> Teva Pharmaceutical Industries saw its first-quarter net profit surge to $713 million, lifted by strong sales of flagship multiple-sclerosis drug Copaxone and its neurological treatment Azilect. Report (sub. req.)

> Impax Laboratories' quarterly profit of $131.5 million handily beat market estimates, helped by higher sales in its generic drugs division and a new drug launch. Report

> Pharmaceutical wholesaler McKesson issued an earnings forecast for fiscal 2011 that exceeds Wall Street estimates, helped by an expected increase in the use of more profitable generic drugs and a favorable anti-trust settlement. Report

 Biotech News

 @FierceBiotech: This was part of the BIO 2010 gift bag--a stuffed E. Coli. What do I do with this? Picture | Follow @FierceBiotech 

 @JohnCFierce: Anybody want to play the cost game on pirfenidone if approved? I've seen ranges of $30-50k. So that means $65k, right? | Follow @JohnCFierce

> Montgomery County pushes $10B biotech 'science city.' Story

> Pharmasset touts promising PhIIa hep C data. Article

> Ironwood offers upbeat PhIII data details on linaclotide. News

> FDA declines to approve Dainippon's epilepsy drug. Report

> Item

Manufacturing News

> J&J's McNeil shuts down plant in another Tylenol recall. Story

> Congress issues 'warning letter' to FDA over 2008 heparin deaths. Article

> Cambridge keeps its biotechs running despite eastern Mass. water main break. Story

> Formatech program donates fill/finish for RegeneRx's MS candidate. News

> Sancilio leads by example in U.S.-made drug rally. Report

Biotech Research News

> NY researchers share $1.5M in biotech seed money. Report

> Team reveals a new mechanism of action for cancer. Story 

> Protein therapy speeds bone healing in mice. News

> Stem cell scientists outline new insights on differentiation. Report

And Finally... A two-week course of the antibiotic rifaximin can provide long-lasting relief for patients with irritable bowel syndrome. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.